122 related articles for article (PubMed ID: 14529894)
1. Thrombin-activatable fibrinolysis inhibitor in kidney transplant recipient with dyslipidemia.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2003 Sep; 35(6):2219-21. PubMed ID: 14529894
[TBL] [Abstract][Full Text] [Related]
2. Thrombin activatable fibrinolysis inhibitor in hypertensive kidney transplant recipients.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2006; 38(1):105-7. PubMed ID: 16504676
[TBL] [Abstract][Full Text] [Related]
3. A possible role of thrombin-activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients.
Hryszko T; Malyszko J; Malyszko JS; Brzosko S; Pawlak K; Mysliwiec M
Nephrol Dial Transplant; 2001 Aug; 16(8):1692-6. PubMed ID: 11477176
[TBL] [Abstract][Full Text] [Related]
4. Some aspects of hemostasis in kidney transplant recipients maintained on cyclosporine, azathioprine, and prednisone in comparison to patients treated with cyclosporine and prednisone.
Malyszko J; Malyszko JS; Hryszko T; Mysliwiec M
Transplant Proc; 2003 Dec; 35(8):2940-2. PubMed ID: 14697944
[TBL] [Abstract][Full Text] [Related]
5. Fluvastin therapy affects TAFI concentration in kidney transplant recipients.
Malyszko J; Malyszko JS; Mysliwiec M
Transpl Int; 2003 Jan; 16(1):53-7. PubMed ID: 12545342
[TBL] [Abstract][Full Text] [Related]
6. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with essential arterial hypertension.
Małyszko J; Tymcio J
Pol Arch Med Wewn; 2008; 118(1-2):36-41. PubMed ID: 18405171
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
[TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy.
Małyszko J; Małyszko JS; Hryszko T; Myśliwiec M
Thromb Haemost; 2004 Mar; 91(3):480-6. PubMed ID: 14983223
[TBL] [Abstract][Full Text] [Related]
9. Structural changes in carotid arteries and impairment of fibrinolysis in hemodialyzed and peritoneally dialyzed patients.
Małyszko J; Łebkowska U; Małyszko JS; Myśliwiec M
Med Sci Monit; 2009 Dec; 15(12):CR644-9. PubMed ID: 19946236
[TBL] [Abstract][Full Text] [Related]
10. [Thrombin activatable fibrinolysis o inhibitor-TAFI- in dialyzed patients with diabetic nephropathy].
Małyszko JS; Małyszko J; Hryszko T; Myśliwiec M
Pol Arch Med Wewn; 2003 Aug; 110(2):843-8. PubMed ID: 14682222
[TBL] [Abstract][Full Text] [Related]
11. Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon.
Binette TM; Taylor FB; Peer G; Bajzar L
Blood; 2007 Nov; 110(9):3168-75. PubMed ID: 17644733
[TBL] [Abstract][Full Text] [Related]
12. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
Coleman JR; Moore EE; Kelher MR; Jones K; Cohen MJ; Banerjee A; Silliman CC
J Trauma Acute Care Surg; 2023 Jun; 94(6):857-862. PubMed ID: 36787438
[TBL] [Abstract][Full Text] [Related]
13. Renal transplant recipients with coronary artery disease exhibit impairment in fibrinolysis and structural changes in carotid arteries.
Malyszko J; Malyszko JS; Hryszko T; Brzosko S; Lebkowska U; Mysliwiec M
Transpl Int; 2005 Feb; 18(2):256-9. PubMed ID: 15691280
[TBL] [Abstract][Full Text] [Related]
14. Dyslipidemias and fibrinolysis.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A
Ital Heart J; 2002 Oct; 3(10):579-86. PubMed ID: 12478815
[TBL] [Abstract][Full Text] [Related]
15. Some aspects of hemostasis in CAPD patients treated with erythropoietin.
Małyszko J; Suchowierska E; Małyszko JS; Myśliwiec M
Kidney Blood Press Res; 2002; 25(4):240-4. PubMed ID: 12424426
[TBL] [Abstract][Full Text] [Related]
16. Treatment with everolimus is associated with a procoagulant state.
Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
[TBL] [Abstract][Full Text] [Related]
17. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin.
Malyszko J; Suchowierska E; Malyszko JS; Mysliwiec M
Perit Dial Int; 2002; 22(5):582-92. PubMed ID: 12455569
[TBL] [Abstract][Full Text] [Related]
18. [Thrombin activatable fibrinolysis inhibitor (TAFI) and its importance in the regulation of fibrinolysis].
Stasko J; Hudecek J; Kubisz P
Vnitr Lek; 2004 Jan; 50(1):36-44. PubMed ID: 15015228
[TBL] [Abstract][Full Text] [Related]
19. Different mechanisms of fibrinolysis impairment among dyslipidemic subjects.
Puccetti L; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Auteri A; Bruni F
Int J Clin Pharmacol Res; 2001; 21(3-4):147-55. PubMed ID: 12067144
[TBL] [Abstract][Full Text] [Related]
20. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.
Nesheim M; Wang W; Boffa M; Nagashima M; Morser J; Bajzar L
Thromb Haemost; 1997 Jul; 78(1):386-91. PubMed ID: 9198184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
